Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-31
2005-05-31
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C530S300000
Reexamination Certificate
active
06900178
ABSTRACT:
A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.
REFERENCES:
patent: 5656420 (1997-08-01), Chien
patent: 6103722 (2000-08-01), Schultz et al.
patent: WO 99/04795 (1999-02-01), None
patent: WO99/56766 (1999-11-01), None
patent: WO99/56767 (1999-11-01), None
Fryer et al., “Opioid-induced cardioprotection against myocardial infraction and arrhythmias: Mitochondrial versus sacrolemmal ATP sensitve potassium channels”, The Journal of Pharmacology and Experimental Therapeutics, 2000, 234(2), 451-57.*
Lazarus et al., “Opioid infidelity: novel opioid peptides with dual high affinity for delta and mu receptors”, in Trends in Neuroscience, 1996, 19, 31-35.*
Kreil, G., “D-amino acids in animal peptides”, in Annual Review of Biochemistry, 1997, 66, pp337-345.*
Fryer et al., “Opioid-induced second window of carioprotection: Potential role of mitochondrial K-ATP channels”, in Circulation Research, 1999, 84, 846-51.*
Pernow et al., “The role of the L-arginine
itric oxide pathway in myocardial ischaemic and reperfusion injury”, in Acta Physiologica Scandinavia, 1999, 167, 151-59.*
Erspamer, et al., Deltorphins: A family of naturally occurring peptides with high affinity and selectivity for δ opioid binding sites, Proceedings of the National Academy of Sciences of the USA 86 (1989) Jul., No. 13, Washington, DC, US.
Schultz, et al., Ischemic Preconditioning and Morphine-induced Cardioprotection Involve the Delta (δ)-opioid Receptor in the Intact Rat Heart, Mol Cell Cardiol 29. 2187-2195 (1997).
Barra et al., Deltorphin, a 17 amino acid opioid peptide from the sking of the Brazilian hylid frog,Phyllomedusa burmeisteri,Peptides (Tarrytown), vol. 15, No. 2, 1994, 199-202.
Bohlinger et al., Interleukin-1 and nitric oxide protect against tumor necrosis factor α-induced liver injury through distinct pathways, Hepatology, 22: 1829-1837, 1995.
Bolling et al., The use of hibernation induction triggers for cardiac transplant preservation, Transplantation 63: 326-329, 1997.
Bolling et al., Delta opioid agonist/antagonist activity and ischemic tolerance, American Heart Association, Atlanta, GA, Nov., 1999.
Bolling et al., Use of “natural” hibernation induction triggers for myocardial protection, Annals Thorac. Surg.: 623-627, 1997.
Bolling et al., Hibernation triggers and myocardial protection, Circulation 98: II-220-II-1224, 1998.
Chien et al., Two-day preservation of major organs with autoperfusion multiorgan preparation and hibernation induction trigger, J. Thorac. Cardiovasc. Surg., 102: 224-234, 1991.
Chien et al., Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE ([D-Ala2, D-Leu5]-enkephalin), J. Thorac. Cardiovasc. Surg., 107: 965-987, 1994.
Crain and Shen, Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability, Pain 84 (2000), 121-131.
Fryer et al., Opioid-induced second window of cardioprotection: Potential role of mitochondrial K-ATP channels, Circ Res. 1999; 84: 846-851.
House et al., A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides, Peptides, (1996) 17 (1): 75-81.
Kavelaitis et al., Opening of potassium channels: The common cardioprotective link between preconditioning and natural hibernation?, Circulation 99: 3079-3085, 1999.
Leist et al., Activation of the 55 kDA TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release, The Journal of Immunology 154: 1307-1316, 1995.
Leist et al., Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-αrequires transcriptional arrest, The Journal of Immunology, 153: 1778-1788, 1994.
Lishmanov et al., Activation of the μ-opioid receptors as a factor increasing heart resistance aganist ischemic and reperfusion damages , Russian J. Physiol. 1998; 84 (11) (Russian w/attached English translation).
Malaguarnera et al., Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus, Journal of Gastroenterology, 32: 211-215, 1997.
Masiov and Lishmanov, Effects of μ- and delta opioid receptor ligands on rhythm and contractility of disorders of isolated rat heart in postischemic period, Kardiologya 1998; 12: 25-30 (Russian w/English translation).
Mayfield and D'Alecy, Delta-1 opioid receptor dependence of acute hypoxic adaptation, J. Pharmacol. Exp. Ther. 268: 74-77, 1994.
Morgan, Regulation of human B lymphocyte activation by opioid peptide hormones: Inhibition of IgG production by opioid receptor class (gamma-kappa-, and delta) selective agonists, Journal of Neuroimmunology, vol. 65, No. 1: 21-30, 1996.
Oeltgen et al, The use of delta-2 opioid agonists for myocardial-ischemia protection, Abstract, Experimental Biology 2000, submitted Nov., 1999.
Oeltgen et al., Extended lung preservation with the use of hibernation trigger factors, Ann. Thorac. Surg. 61: 1488-93, 1996.
Reisine et al., Opioid analgesics and antagonists, Goodman and Gilman's : The Pharmacological Basis of Therapeutics, 9th Ed., 1995, Section III Drugs Acting on the Central Nervous System, 23: 521-554.
Root et al., “Septicemia and septic shock”, Part Five of Infectious Diseases, Section 3, Clinical Syndromes,Harrison's Principles of Internal Medicine,12th Ed., McGraw-Hill, 1991, 502-507.
Schultz et al., Ischemic preconditioning in the intact rat heart is mediated by δ 1- but not μ or χ-opioid receptors, Circ 97: 1282-1289, 1998.
Schultz et al., Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart, Circ. Research. 78: 1100-1104, 1996.
Schultz et al., Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts, Am. J. Physiol. 268 (Heart Circ. Physiol. 3): H2157-H2161, 1995.
Schultz et al., Involvement of activation of ATP-dependent potassium channels in ischemiec preconditioning in swine, Am. J. Physiol. 267: H1341-1352, 1994.
Schwartz et al., Delta opioid receptors and low temperature myocardial protection, Ann. Thorac. Surg. 68: 2089-92, 1999.
Stefano et al., Delta-2 opioid receptor subtype on human vascular endothelium uncouples morphine stimulated nitric oxide release, International J. Cardiology 64: Suppl. 1, S43-S51, 1998.
Thomas et al., Structure-activity relationships of a series of 'D-Ala2-deltorphin I and II analogues: in vitro blood-brain barrier permeability and stability, Journal of Pharmacology and Experiential Therapy, vol. 281, No. 2: 817-825, 1997.
Thornton, Jr. et al., Opioid peptides and primary biliary cirrhosis, BMJ, vol. 297, No. 6662: 1501-4, 1988.
Toombs et al., Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide, Cardio. Res. 27: 617-622, 1993.
Tsutsui et al., IL-18 accounts for both TNF-α- and fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice, The Journal of Immunology, 159: 3961-3967, 1997.
VanWinkle et al., Cardioprotection provided by adenosine receptor activation is abolished by blockade of the K-ATP channel, Am. J. Physiol. 266: H829-H839, 1994.
Wu et al., Delta opioid extends hypothermic preservation time of the lung, J. Thorac. Cardiovasc. Surg. 1996; 111: 259-267.
Zhao and Bhargava, Effects of multiple intracerebroventricular injections of (D-Pen2, D-Pen5) enkephalin and [D-Ala2, Glu4] deltorphin II on tolerance to their analgesic action and on brain δ-opioid receptors, Brain Research: 745 (1997) 2
Bishop Paul D.
Kindy Mark S.
Oeltgen Peter R.
Sanchez Juan A.
Mayer Suzanne M.
University of Kentucky Research Foundation
Wax Robert A.
Wood Herron & Evans L.L.P.
LandOfFree
Protection against ischemia and reperfusion injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection against ischemia and reperfusion injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection against ischemia and reperfusion injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3429155